STAT+: The biotech scorecard for the third quarter: 18 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:
The readout of Alnylam Pharmaceuticals’ APOLLO-B Phase 3 study is one of the biggest clinical trial catalysts of the year. The study is attempting to expand the use of Alnylam’s approved RNA-interference medicine Onpattro to encompass a significantly larger group of patients with transthyretin amyloidosis cardiomyopathy, or ATTR-CM, a progressive heart disease caused by the buildup of a toxic protein. APOLLO-B is also high risk, given the uncertainties raised last year when a similar study conducted by BridgeBio delivered negative results.
